Which has better earnings & valuation, OPRX or PHR?

OptimizeRx has higher earnings, but lower revenue than Phreesia. OptimizeRx is trading at a lower price-to-earnings ratio than Phreesia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OptimizeRx $109.43M 1.48 $5.13M $0.23 37.26 Phreesia $480.59M 1.30 $2.31M $0.17 59.32

Is OPRX or PHR more profitable?

OptimizeRx has a net margin of 4.66% compared to Phreesia's net margin of 2.06%. OptimizeRx's return on equity of 9.44% beat Phreesia's return on equity. Company Net Margins Return on Equity Return on Assets OptimizeRx 4.66% 9.44% 7.11% Phreesia 2.06% 5.22% 3.02%

Does the media prefer OPRX or PHR?

In the previous week, Phreesia had 2 more articles in the media than OptimizeRx. MarketBeat recorded 6 mentions for Phreesia and 4 mentions for OptimizeRx. Phreesia's average media sentiment score of 0.54 beat OptimizeRx's score of 0.25 indicating that Phreesia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OptimizeRx 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Phreesia 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend OPRX or MDRX?

OptimizeRx currently has a consensus price target of $11.57, suggesting a potential upside of 35.02%. Given OptimizeRx's stronger consensus rating and higher possible upside, analysts clearly believe OptimizeRx is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OptimizeRx 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.56 Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, OPRX or MDRX?

OptimizeRx has higher earnings, but lower revenue than Veradigm. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OptimizeRx $109.43M 1.48 $5.13M $0.23 37.26 Veradigm $1.53B 0.40 N/A N/A N/A

Does the media favor OPRX or WEAV?

In the previous week, Weave Communications had 1 more articles in the media than OptimizeRx. MarketBeat recorded 5 mentions for Weave Communications and 4 mentions for OptimizeRx. Weave Communications' average media sentiment score of 0.51 beat OptimizeRx's score of 0.25 indicating that Weave Communications is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OptimizeRx 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Weave Communications 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, OPRX or NRC?

National Research has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OptimizeRx $109.43M 1.48 $5.13M $0.23 37.26 National Research $137.39M 3.37 $11.60M $0.25 81.40

Does the media prefer OPRX or NRC?

In the previous week, OptimizeRx had 1 more articles in the media than National Research. MarketBeat recorded 4 mentions for OptimizeRx and 3 mentions for National Research. National Research's average media sentiment score of 0.55 beat OptimizeRx's score of 0.25 indicating that National Research is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OptimizeRx 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral National Research 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer OPRX or EVH?

In the previous week, OptimizeRx had 2 more articles in the media than Evolent Health. MarketBeat recorded 4 mentions for OptimizeRx and 2 mentions for Evolent Health. OptimizeRx's average media sentiment score of 0.25 beat Evolent Health's score of 0.25 indicating that OptimizeRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OptimizeRx 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evolent Health 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

OptimizeRx (OPRX) Competitors

$8.57 0.00 (0.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$8.56 -0.01 (-0.14%)

As of 10/2/2026 07:30 PM Eastern

Compare

OPRX vs. PHR, MDRX, WEAV, NRC, and EVH

Should you buy OptimizeRx stock or one of its competitors? OptimizeRx's main competitors and comparable companies include Phreesia (PHR), Veradigm (MDRX), Weave Communications (WEAV), National Research (NRC), and Evolent Health (EVH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does OptimizeRx compare to Phreesia?

OptimizeRx (NASDAQ:OPRX) and Phreesia (NYSE:PHR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

OptimizeRx has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Phreesia has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

76.5% of OptimizeRx shares are held by institutional investors. Comparatively, 92.1% of Phreesia shares are held by institutional investors. 7.5% of OptimizeRx shares are held by company insiders. Comparatively, 5.2% of Phreesia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

OptimizeRx has higher earnings, but lower revenue than Phreesia. OptimizeRx is trading at a lower price-to-earnings ratio than Phreesia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$109.43M	1.48	$5.13M	$0.23	37.26
Phreesia	$480.59M	1.30	$2.31M	$0.17	59.32

In the previous week, Phreesia had 2 more articles in the media than OptimizeRx. MarketBeat recorded 6 mentions for Phreesia and 4 mentions for OptimizeRx. Phreesia's average media sentiment score of 0.54 beat OptimizeRx's score of 0.25 indicating that Phreesia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OptimizeRx	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Phreesia	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OptimizeRx currently has a consensus target price of $11.57, suggesting a potential upside of 35.02%. Phreesia has a consensus target price of $14.00, suggesting a potential upside of 38.82%. Given Phreesia's higher possible upside, analysts plainly believe Phreesia is more favorable than OptimizeRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Phreesia	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.37

OptimizeRx has a net margin of 4.66% compared to Phreesia's net margin of 2.06%. OptimizeRx's return on equity of 9.44% beat Phreesia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OptimizeRx	4.66%	9.44%	7.11%
Phreesia	2.06%	5.22%	3.02%

Summary

OptimizeRx beats Phreesia on 9 of the 16 factors compared between the two stocks.

How does OptimizeRx compare to Veradigm?

OptimizeRx (NASDAQ:OPRX) and Veradigm (NASDAQ:MDRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

OptimizeRx has higher earnings, but lower revenue than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$109.43M	1.48	$5.13M	$0.23	37.26
Veradigm	$1.53B	0.40	N/A	N/A	N/A

76.5% of OptimizeRx shares are held by institutional investors. 7.5% of OptimizeRx shares are held by insiders. Comparatively, 2.3% of Veradigm shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

OptimizeRx currently has a consensus price target of $11.57, suggesting a potential upside of 35.02%. Given OptimizeRx's stronger consensus rating and higher possible upside, analysts clearly believe OptimizeRx is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, OptimizeRx had 4 more articles in the media than Veradigm. MarketBeat recorded 4 mentions for OptimizeRx and 0 mentions for Veradigm. OptimizeRx's average media sentiment score of 0.25 beat Veradigm's score of 0.00 indicating that OptimizeRx is being referred to more favorably in the media.

Company	Overall Sentiment
OptimizeRx	Neutral
Veradigm	Neutral

OptimizeRx has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Veradigm has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

OptimizeRx has a net margin of 4.66% compared to Veradigm's net margin of 0.00%. OptimizeRx's return on equity of 9.44% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OptimizeRx	4.66%	9.44%	7.11%
Veradigm	N/A	N/A	N/A

Summary

OptimizeRx beats Veradigm on 13 of the 14 factors compared between the two stocks.

How does OptimizeRx compare to Weave Communications?

OptimizeRx (NASDAQ:OPRX) and Weave Communications (NYSE:WEAV) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

In the previous week, Weave Communications had 1 more articles in the media than OptimizeRx. MarketBeat recorded 5 mentions for Weave Communications and 4 mentions for OptimizeRx. Weave Communications' average media sentiment score of 0.51 beat OptimizeRx's score of 0.25 indicating that Weave Communications is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OptimizeRx	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Weave Communications	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OptimizeRx currently has a consensus price target of $11.57, suggesting a potential upside of 35.02%. Weave Communications has a consensus price target of $7.84, suggesting a potential upside of 6.31%. Given OptimizeRx's stronger consensus rating and higher possible upside, equities analysts clearly believe OptimizeRx is more favorable than Weave Communications.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Weave Communications	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13

OptimizeRx has a net margin of 4.66% compared to Weave Communications' net margin of -7.97%. OptimizeRx's return on equity of 9.44% beat Weave Communications' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OptimizeRx	4.66%	9.44%	7.11%
Weave Communications	-7.97%	-21.14%	-8.41%

OptimizeRx has higher earnings, but lower revenue than Weave Communications. Weave Communications is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$109.43M	1.48	$5.13M	$0.23	37.26
Weave Communications	$239.02M	2.47	-$28.05M	-$0.25	N/A

76.5% of OptimizeRx shares are owned by institutional investors. Comparatively, 86.8% of Weave Communications shares are owned by institutional investors. 7.5% of OptimizeRx shares are owned by insiders. Comparatively, 16.4% of Weave Communications shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

OptimizeRx has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Weave Communications has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market.

Summary

OptimizeRx beats Weave Communications on 9 of the 16 factors compared between the two stocks.

How does OptimizeRx compare to National Research?

OptimizeRx (NASDAQ:OPRX) and National Research (NASDAQ:NRC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

OptimizeRx has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, National Research has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

In the previous week, OptimizeRx had 1 more articles in the media than National Research. MarketBeat recorded 4 mentions for OptimizeRx and 3 mentions for National Research. National Research's average media sentiment score of 0.55 beat OptimizeRx's score of 0.25 indicating that National Research is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OptimizeRx	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
National Research	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

National Research has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$109.43M	1.48	$5.13M	$0.23	37.26
National Research	$137.39M	3.37	$11.60M	$0.25	81.40

OptimizeRx presently has a consensus price target of $11.57, indicating a potential upside of 35.02%. National Research has a consensus price target of $26.00, indicating a potential upside of 27.76%. Given OptimizeRx's stronger consensus rating and higher probable upside, equities analysts clearly believe OptimizeRx is more favorable than National Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
National Research	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

OptimizeRx has a net margin of 4.66% compared to National Research's net margin of 4.18%. National Research's return on equity of 164.26% beat OptimizeRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OptimizeRx	4.66%	9.44%	7.11%
National Research	4.18%	164.26%	14.67%

76.5% of OptimizeRx shares are held by institutional investors. Comparatively, 47.3% of National Research shares are held by institutional investors. 7.5% of OptimizeRx shares are held by company insiders. Comparatively, 9.2% of National Research shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

National Research beats OptimizeRx on 9 of the 16 factors compared between the two stocks.

How does OptimizeRx compare to Evolent Health?

OptimizeRx (NASDAQ:OPRX) and Evolent Health (NYSE:EVH) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

OptimizeRx has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Evolent Health has a beta of 1.02, indicating that its stock price is 2% more volatile than the broader market.

In the previous week, OptimizeRx had 2 more articles in the media than Evolent Health. MarketBeat recorded 4 mentions for OptimizeRx and 2 mentions for Evolent Health. OptimizeRx's average media sentiment score of 0.25 beat Evolent Health's score of 0.25 indicating that OptimizeRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OptimizeRx	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evolent Health	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

76.5% of OptimizeRx shares are held by institutional investors. 7.5% of OptimizeRx shares are held by insiders. Comparatively, 1.5% of Evolent Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

OptimizeRx has higher earnings, but lower revenue than Evolent Health. Evolent Health is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$109.43M	1.48	$5.13M	$0.23	37.26
Evolent Health	$1.88B	0.21	-$534.51M	-$4.57	N/A

OptimizeRx has a net margin of 4.66% compared to Evolent Health's net margin of -24.08%. OptimizeRx's return on equity of 9.44% beat Evolent Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OptimizeRx	4.66%	9.44%	7.11%
Evolent Health	-24.08%	-4.27%	-1.06%

OptimizeRx presently has a consensus price target of $11.57, indicating a potential upside of 35.02%. Evolent Health has a consensus price target of $5.96, indicating a potential upside of 71.68%. Given Evolent Health's stronger consensus rating and higher possible upside, analysts clearly believe Evolent Health is more favorable than OptimizeRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Evolent Health	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

OptimizeRx beats Evolent Health on 12 of the 16 factors compared between the two stocks.

Get OptimizeRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OPRX vs. The Competition

Export

Metric	OptimizeRx	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$161.46M	$1.74B	$7.16B	$13.28B
Dividend Yield	N/A	3.97%	2.53%	17.33%
P/E Ratio	37.26	20.33	274.69	26.04
Price / Sales	1.48	87.60	610.13	91.98
Price / Cash	8.71	31.81	27.22	34.69
Price / Book	1.25	6.17	10.97	6.34
Net Income	$5.13M	-$18.66M	$3.50B	$381.73M
7 Day Performance	9.73%	-1.70%	-1.84%	-0.72%
1 Month Performance	8.89%	-1.33%	-6.21%	-4.68%
1 Year Performance	-54.29%	-21.68%	8.03%	1.57%

OptimizeRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OPRX OptimizeRx	4.3103 of 5 stars	$8.57 flat	$11.57 +35.0%	-54.3%	$161.46M	$109.43M	37.26	105
PHR Phreesia	3.691 of 5 stars	$10.15 -2.1%	$14.00 +38.0%	-56.6%	$629.89M	$480.59M	59.70	1,789	Gap Up
MDRX Veradigm	N/A	$5.05 +1.0%	N/A	+6.4%	$617.62M	$1.53B	23.25	8,000	News Coverage Gap Up
WEAV Weave Communications	2.0176 of 5 stars	$7.38 -0.1%	$7.84 +6.3%	+10.8%	$590M	$239.02M	N/A	904	News Coverage
NRC National Research	3.0348 of 5 stars	$20.37 -4.5%	$26.00 +27.6%	+66.7%	$463.53M	$137.39M	81.50	357	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OPRX) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OptimizeRx (OPRX) Competitors

OPRX vs. PHR, MDRX, WEAV, NRC, and EVH

How does OptimizeRx compare to Phreesia?

Summary

How does OptimizeRx compare to Veradigm?

Summary

How does OptimizeRx compare to Weave Communications?

Summary

How does OptimizeRx compare to National Research?

Summary

How does OptimizeRx compare to Evolent Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPRX vs. The Competition

OptimizeRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OptimizeRx (OPRX) Competitors

OPRX vs. PHR, MDRX, WEAV, NRC, and EVH

How does OptimizeRx compare to Phreesia?

Which has more risk & volatility, OPRX or PHR?

Do insiders and institutionals have more ownership in OPRX or PHR?

Which has better earnings & valuation, OPRX or PHR?

Does the media prefer OPRX or PHR?

Do analysts prefer OPRX or PHR?

Is OPRX or PHR more profitable?

Summary

How does OptimizeRx compare to Veradigm?

Which has preferable valuation and earnings, OPRX or MDRX?

Do insiders and institutionals hold more shares of OPRX or MDRX?

Do analysts recommend OPRX or MDRX?

Does the media prefer OPRX or MDRX?

Which has more risk and volatility, OPRX or MDRX?

Is OPRX or MDRX more profitable?

Summary

How does OptimizeRx compare to Weave Communications?

Does the media favor OPRX or WEAV?

Do analysts recommend OPRX or WEAV?

Is OPRX or WEAV more profitable?

Which has better valuation and earnings, OPRX or WEAV?

Do insiders & institutionals have more ownership in OPRX or WEAV?

Which has more risk & volatility, OPRX or WEAV?

Summary

How does OptimizeRx compare to National Research?

Which has more volatility and risk, OPRX or NRC?

Does the media prefer OPRX or NRC?

Which has better earnings & valuation, OPRX or NRC?

Do analysts recommend OPRX or NRC?

Is OPRX or NRC more profitable?

Do insiders & institutionals believe in OPRX or NRC?

Summary

How does OptimizeRx compare to Evolent Health?

Which has more volatility & risk, OPRX or EVH?

Does the media prefer OPRX or EVH?

Do institutionals & insiders believe in OPRX or EVH?

Which has stronger earnings and valuation, OPRX or EVH?

Is OPRX or EVH more profitable?

Do analysts recommend OPRX or EVH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPRX vs. The Competition

OptimizeRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools